Skip to content
RUO Report
ResearchReviewsPeptidesMethodologyAbout

Sermorelin

Also: Sermorelin acetate, GHRH (1-29), GHRH 1-29, GRF (1-29), Geref, Sermorelinum

Research PeptideLimitedSynthetic GHRH analog (GHRH 1-29 / GRF 1-29). Historically encountered as a regulated pharmaceutical product (e.g., the diagnostic agent marketed as Geref) that has since been discontinued in the United States; it is now most often encountered as a research-use-only compound. The literature includes dated clinical pharmacology of the GH/IGF-1 axis alongside preclinical and in-vitro/mechanistic studies, and the human-era data does not transfer to research-use settings or to any contemporary application. Material sold under this name is labeled for laboratory research only and not for human or veterinary use; regulatory, legal, and sourcing details require independent editorial verification.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29), described in the research literature as the biologically active fragment of GHRH. In research contexts it is discussed as a growth hormone secretagogue that is reported to act on pituitary GHRH receptors rather than supplying growth hormone directly. The available body of work spans dated/historical clinical pharmacology together with preclinical and in-vitro/mechanistic studies, and findings require careful interpretation due to study-design and translation limitations. This profile is educational and research-focused only and does not describe, recommend, or imply any use in humans or animals, nor any safety, effectiveness, or outcome.

Mechanism as described in the literature

Sermorelin (GHRH 1-29) is characterized in the research literature as an analog of endogenous growth hormone-releasing hormone. Mechanistic and pharmacological studies report that it binds the GHRH receptor on somatotroph cells of the anterior pituitary, where receptor engagement is associated with downstream signaling (commonly described via the cAMP/PKA pathway) that is linked, in these models, to the synthesis and pulsatile release of growth hormone. These are descriptions of a reported molecular mechanism and are not statements about any human or animal outcome, benefit, or application.

Because it is described as acting upstream at the pituitary rather than introducing growth hormone directly, the research framing often contrasts it with exogenous growth hormone and notes that GHRH-receptor pathways are reported to remain subject to physiological feedback (for example via somatostatin and IGF-1). These accounts are drawn largely from in-vitro, preclinical, and dated clinical-pharmacology models; translation to any specific real-world outcome is not established here and evidence should be interpreted cautiously given study-design and translation limitations.

Research areas

  • Growth hormone / IGF-1 axis regulation and somatotroph signaling (mechanistic)
  • Pituitary GHRH receptor pharmacology in vitro
  • Neuroendocrine GH pulsatility and feedback in preclinical models
  • Historical clinical pharmacology of GH-axis diagnostic agents (dated)
  • Analytical characterization, peptide stability, and documentation/testing visibility

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is sermorelin?+

It is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), described in the research literature as a growth hormone secretagogue that is reported to act on pituitary GHRH receptors. This entry is educational and research-focused only and does not describe, recommend, or imply any human or animal use.

How is sermorelin described differently from growth hormone itself?+

In mechanistic terms, the literature frames sermorelin as reported to act upstream at the pituitary GHRH receptor on the body's own growth-hormone signaling, whereas exogenous growth hormone introduces the hormone directly. This is a mechanistic distinction reported in studies, not a statement about safety, effectiveness, or any outcome.

Is the evidence for sermorelin strong?+

No. Although sermorelin has a dated clinical-pharmacology record, the research-use evidence base is limited and often historical, and findings should be interpreted cautiously given study-design and translation limitations. References here are intentionally left empty for editorial source verification.